Clinical curative effect and quality of life evaluation of dupilumab in treating children with atopic dermatitis and its effect on IgE levels, eosinophil count, Th2 cytokines (IL-4 and IL-13), and thymus and activation-regulated chemokine.

IF 1.4 4区 医学 Q3 ALLERGY
Postepy Dermatologii I Alergologii Pub Date : 2025-02-01 Epub Date: 2024-12-20 DOI:10.5114/ada.2024.146176
Yougang Ren, Zhongxiao Wu, Mouzhe Yang, Haitao Lou
{"title":"Clinical curative effect and quality of life evaluation of dupilumab in treating children with atopic dermatitis and its effect on IgE levels, eosinophil count, Th2 cytokines (IL-4 and IL-13), and thymus and activation-regulated chemokine.","authors":"Yougang Ren, Zhongxiao Wu, Mouzhe Yang, Haitao Lou","doi":"10.5114/ada.2024.146176","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Atopic dermatitis (AD) is a common chronic skin inflammatory disease. The traditional treatment shows limited effect and side effects. Dupilumab is a monoclonal antibody immunotherapy targeting IL-4 and IL-13, which may become a new direction for treating AD.</p><p><strong>Aim: </strong>This study was to explore the clinical curative effect of dupilumab in the treatment of children with AD, and its influence on the quality of life (QoL) of children.</p><p><strong>Material and methods: </strong>54 children with AD, who were treated in the outpatient and inpatient departments of the hospital from August 2023 to July 2024, were included in this study. These children were treated with dupilumab, and their clinical curative effect as well as QoL were evaluated through relevant scales as well as the IgE, eosinophil counts, and Th2 cytokine levels.</p><p><strong>Results: </strong>After treatment, Eczema Area and Severity Index (EASI) score was 8.8 ±4.5, Scoring Atopic Dermatitis (SCORAD) score was 15.1 ±8.4, and itching Numeric Rating Scale (NRS) score was 1.1 ±0.7. Compared with those before treatment, the scores of 25.4 ±6.2, 38.6 ±10.3, and 6.9 ±2.2 were highly decreased with differences being statistically significant (<i>p</i> < 0.05). Only 3 cases had an Investigator's Global Assessment (IGA) ≥ 3, which was greatly reduced than that before treatment (<i>p</i> < 0.05). 5 cases had the adverse reaction of conjunctivitis after treatment, Patient-Oriented Eczema Measure (POEM) score was 4.8 ±1.6, and Dermatology Life Quality Index (DLQI) was scored as 3.3 ±1.8. These were observably lower than those before the patients were treated, exhibiting significant differences (<i>p</i> < 0.05). There were significant reductions in IgE levels, eosinophil count, Th2 cytokines (IL-4 and IL-13), and thymus and activation-regulated chemokine (TARC) after treatment (<i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>Dupilumab could effectively treat children with AD and improve their QoL, so it had a clinical application value.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"42 1","pages":"62-67"},"PeriodicalIF":1.4000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921923/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Postepy Dermatologii I Alergologii","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5114/ada.2024.146176","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/20 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Atopic dermatitis (AD) is a common chronic skin inflammatory disease. The traditional treatment shows limited effect and side effects. Dupilumab is a monoclonal antibody immunotherapy targeting IL-4 and IL-13, which may become a new direction for treating AD.

Aim: This study was to explore the clinical curative effect of dupilumab in the treatment of children with AD, and its influence on the quality of life (QoL) of children.

Material and methods: 54 children with AD, who were treated in the outpatient and inpatient departments of the hospital from August 2023 to July 2024, were included in this study. These children were treated with dupilumab, and their clinical curative effect as well as QoL were evaluated through relevant scales as well as the IgE, eosinophil counts, and Th2 cytokine levels.

Results: After treatment, Eczema Area and Severity Index (EASI) score was 8.8 ±4.5, Scoring Atopic Dermatitis (SCORAD) score was 15.1 ±8.4, and itching Numeric Rating Scale (NRS) score was 1.1 ±0.7. Compared with those before treatment, the scores of 25.4 ±6.2, 38.6 ±10.3, and 6.9 ±2.2 were highly decreased with differences being statistically significant (p < 0.05). Only 3 cases had an Investigator's Global Assessment (IGA) ≥ 3, which was greatly reduced than that before treatment (p < 0.05). 5 cases had the adverse reaction of conjunctivitis after treatment, Patient-Oriented Eczema Measure (POEM) score was 4.8 ±1.6, and Dermatology Life Quality Index (DLQI) was scored as 3.3 ±1.8. These were observably lower than those before the patients were treated, exhibiting significant differences (p < 0.05). There were significant reductions in IgE levels, eosinophil count, Th2 cytokines (IL-4 and IL-13), and thymus and activation-regulated chemokine (TARC) after treatment (p < 0.05).

Conclusions: Dupilumab could effectively treat children with AD and improve their QoL, so it had a clinical application value.

杜匹单抗治疗儿童特应性皮炎的临床疗效及生活质量评价及其对IgE水平、嗜酸性粒细胞计数、Th2细胞因子(IL-4、IL-13)、胸腺及活化调节趋化因子的影响
特应性皮炎(AD)是一种常见的慢性皮肤炎症性疾病。传统的治疗方法效果有限,副作用大。Dupilumab是一种靶向IL-4和IL-13的单克隆抗体免疫疗法,可能成为治疗AD的新方向。目的:探讨杜匹单抗治疗儿童AD的临床疗效及其对儿童生活质量的影响。材料与方法:本研究纳入了2023年8月至2024年7月在该院门诊和住院部治疗的54例AD患儿。采用dupilumab治疗患儿,通过相关量表及IgE、嗜酸性粒细胞计数、Th2细胞因子水平评价患儿的临床疗效和生活质量。结果:治疗后湿疹面积及严重程度指数(EASI)评分为8.8±4.5分,特应性皮炎评分(SCORAD)评分为15.1±8.4分,瘙痒数值评定量表(NRS)评分为1.1±0.7分。与治疗前比较,25.4±6.2分、38.6±10.3分、6.9±2.2分均显著降低,差异有统计学意义(p < 0.05)。仅有3例患者IGA≥3,较治疗前显著降低(p < 0.05)。5例患者治疗后出现结膜炎不良反应,患者湿疹量表(Patient-Oriented Eczema Measure, POEM)评分为4.8±1.6分,皮肤病生活质量指数(Dermatology Life Quality Index, DLQI)评分为3.3±1.8分。与治疗前比较,差异有统计学意义(p < 0.05)。治疗后患者IgE水平、嗜酸性粒细胞计数、Th2细胞因子(IL-4、IL-13)、胸腺及活化调节趋化因子(TARC)均显著降低(p < 0.05)。结论:Dupilumab能有效治疗AD患儿,改善患儿生活质量,具有临床应用价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.60
自引率
7.10%
发文量
107
审稿时长
6-12 weeks
期刊介绍: Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii is a bimonthly aimed at allergologists and dermatologists.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信